Literature DB >> 16247049

Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.

C R Jack1, M M Shiung, S D Weigand, P C O'Brien, J L Gunter, B F Boeve, D S Knopman, G E Smith, R J Ivnik, E G Tangalos, R C Petersen.   

Abstract

OBJECTIVE: To test the hypothesis that the atrophy rate measured from serial MRI studies is associated with time to subsequent clinical conversion to a more impaired state in both cognitively healthy elderly subjects and in subjects with amnestic mild cognitive impairment (MCI).
METHODS: Ninety-one healthy elderly patients and 72 patients with amnestic MCI who met inclusion criteria were identified from the Mayo Alzheimer's Disease Research Center and Alzheimer's Disease Patient Registry. Atrophy rates of four different brain structures--hippocampus, entorhinal cortex, whole brain, and ventricle--were measured from a pair of MRI studies separated by 1 to 2 years. The time of the second scan marked the beginning of the clinical observation period.
RESULTS: During follow-up, 13 healthy patients converted to MCI or Alzheimer disease (AD), whereas 39 MCI subjects converted to AD. Among those healthy at baseline, only larger ventricular annual percent volume change (APC) was associated with a higher risk of conversion (hazard ratio for a 1-SD increase 1.9, p = 0.03). Among MCI subjects, both greater ventricular volume APC (hazard ratio for a 1-SD increase 1.7, p < 0.001) and greater whole brain APC (hazard ratio for a 1-SD increase 1.4, p = 0.007) increased the risk of conversion to AD. Both ventricular APC (hazard ratio for a 1-SD increase 1.59, p = 0.001) and whole brain APC (hazard ratio for a 1-SD increase 1.32, p = 0.009) provided additional predictive information to covariate-adjusted cross-sectional hippocampal volume at baseline about the risk of converting from MCI to AD. DISCUSSION: Higher whole brain and ventricle atrophy rates 1 to 2 years before baseline are associated with an increased hazard of conversion to a more impaired state. Combining a measure of hippocampal volume at baseline with a measure of either whole brain or ventricle atrophy rates from serial MRI scans provides complimentary predictive information about the hazard of subsequent conversion from mild cognitive impairment to Alzheimer disease. However, overlap among those who did vs those who did not convert indicate that these measures are unlikely to provide absolute prognostic information for individual patients.

Entities:  

Mesh:

Year:  2005        PMID: 16247049      PMCID: PMC2753547          DOI: 10.1212/01.wnl.0000180958.22678.91

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment.

Authors:  P J Visser; P Scheltens; F R Verhey; B Schmand; L J Launer; J Jolles; C Jonker
Journal:  J Neurol       Date:  1999-06       Impact factor: 4.849

2.  MRI measures of entorhinal cortex vs hippocampus in preclinical AD.

Authors:  R J Killiany; B T Hyman; T Gomez-Isla; M B Moss; R Kikinis; F Jolesz; R Tanzi; K Jones; M S Albert
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

3.  Mayo Clinic Alzheimer's Disease Patient Registry.

Authors:  R C Petersen; E Kokmen; E Tangalos; R J Ivnik; L T Kurland
Journal:  Aging (Milano)       Date:  1990-12

4.  MR imaging-based volume measurements of the hippocampal formation and anterior temporal lobe: validation studies.

Authors:  C R Jack; M D Bentley; C K Twomey; A R Zinsmeister
Journal:  Radiology       Date:  1990-07       Impact factor: 11.105

5.  The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation.

Authors:  M J de Leon; J Golomb; A E George; A Convit; C Y Tarshish; T McRae; S De Santi; G Smith; S H Ferris; M Noz
Journal:  AJNR Am J Neuroradiol       Date:  1993 Jul-Aug       Impact factor: 3.825

6.  MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease.

Authors:  B C Dickerson; I Goncharova; M P Sullivan; C Forchetti; R S Wilson; D A Bennett; L A Beckett; L deToledo-Morrell
Journal:  Neurobiol Aging       Date:  2001 Sep-Oct       Impact factor: 4.673

7.  Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.

Authors:  R J Killiany; T Gomez-Isla; M Moss; R Kikinis; T Sandor; F Jolesz; R Tanzi; K Jones; B T Hyman; M S Albert
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422

8.  Methodological considerations for measuring rates of brain atrophy.

Authors:  Jeffrey L Gunter; Maria M Shiung; Armando Manduca; Clifford R Jack
Journal:  J Magn Reson Imaging       Date:  2003-07       Impact factor: 4.813

9.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.

Authors:  C R Jack; M M Shiung; J L Gunter; P C O'Brien; S D Weigand; D S Knopman; B F Boeve; R J Ivnik; G E Smith; R H Cha; E G Tangalos; R C Petersen
Journal:  Neurology       Date:  2004-02-24       Impact factor: 9.910

10.  Assessing the onset of structural change in familial Alzheimer's disease.

Authors:  Jonathan M Schott; Nick C Fox; Chris Frost; Rachael I Scahill; John C Janssen; Dennis Chan; Rhian Jenkins; Martin N Rossor
Journal:  Ann Neurol       Date:  2003-02       Impact factor: 10.422

View more
  204 in total

1.  The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects.

Authors:  Mert R Sabuncu; Randy L Buckner; Jordan W Smoller; Phil Hyoun Lee; Bruce Fischl; Reisa A Sperling
Journal:  Cereb Cortex       Date:  2011-12-13       Impact factor: 5.357

Review 2.  Alliance for aging research AD biomarkers work group: structural MRI.

Authors:  Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

Review 3.  Quantitative structural MRI for early detection of Alzheimer's disease.

Authors:  Linda K McEvoy; James B Brewer
Journal:  Expert Rev Neurother       Date:  2010-11       Impact factor: 4.618

4.  Dynamic Bayesian network modeling for longitudinal brain morphometry.

Authors:  Rong Chen; Susan M Resnick; Christos Davatzikos; Edward H Herskovits
Journal:  Neuroimage       Date:  2011-09-22       Impact factor: 6.556

5.  Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.

Authors:  Lisa Mosconi; Juha O Rinne; Wai H Tsui; Valentina Berti; Yi Li; Huiyu Wang; John Murray; Noora Scheinin; Kjell Någren; Schantel Williams; Lidia Glodzik; Susan De Santi; Shankar Vallabhajosula; Mony J de Leon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

Review 6.  REVIEW: Apathy diagnosis, assessment, and treatment in Alzheimer's disease.

Authors:  Philippe H Robert; Emmanuel Mulin; Patrick Malléa; Renaud David
Journal:  CNS Neurosci Ther       Date:  2010-10       Impact factor: 5.243

Review 7.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

8.  MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths.

Authors:  Jorge Jovicich; Silvester Czanner; Xiao Han; David Salat; Andre van der Kouwe; Brian Quinn; Jenni Pacheco; Marilyn Albert; Ronald Killiany; Deborah Blacker; Paul Maguire; Diana Rosas; Nikos Makris; Randy Gollub; Anders Dale; Bradford C Dickerson; Bruce Fischl
Journal:  Neuroimage       Date:  2009-02-20       Impact factor: 6.556

9.  Variation in Variables that Predict Progression from MCI to AD Dementia over Duration of Follow-up.

Authors:  Shanshan Li; Ozioma Okonkwo; Marilyn Albert; Mei-Cheng Wang
Journal:  Am J Alzheimers Dis (Columbia)       Date:  2013

10.  Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size.

Authors:  Peng Yu; Jia Sun; Robin Wolz; Diane Stephenson; James Brewer; Nick C Fox; Patricia E Cole; Clifford R Jack; Derek L G Hill; Adam J Schwarz
Journal:  Neurobiol Aging       Date:  2013-10-03       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.